Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 7
2005 10
2006 13
2007 13
2008 7
2009 16
2010 12
2011 13
2012 19
2013 16
2014 14
2015 25
2016 27
2017 15
2018 25
2019 30
2020 27
2021 28
2022 30
2023 22
2024 13
2025 9
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Results by year

Filters applied: . Clear all
Page 1
The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. Wang Y, et al. Among authors: liu zg. Clin Cancer Res. 2019 Mar 15;25(6):1709-1717. doi: 10.1158/1078-0432.CCR-18-2581. Epub 2018 Nov 9. Clin Cancer Res. 2019. PMID: 30413527 Free PMC article. Review.
Recent progress of nano-drugs in neutron capture therapy.
Zhou YT, Cheng K, Liu B, Cao YC, Fan JX, Liu ZG, Zhao YD. Zhou YT, et al. Among authors: liu zg. Theranostics. 2024 May 19;14(8):3193-3212. doi: 10.7150/thno.95034. eCollection 2024. Theranostics. 2024. PMID: 38855185 Free PMC article. Review.
Galectin-1 inhibits oral-intestinal allergy syndrome.
Xie RD, Xu LZ, Yang LT, Wang S, Liu Q, Liu ZG, Yang PC. Xie RD, et al. Among authors: liu zg. Oncotarget. 2017 Feb 21;8(8):13214-13222. doi: 10.18632/oncotarget.14571. Oncotarget. 2017. PMID: 28086216 Free PMC article.
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
You R, Xu GQ, Ding X, Liang JH, Liu ZG, Zou X, Liu YP, Hu GY, Liu YM, Duan CY, Liu LZ, Zhang WJ, Liu Q, Li HF, Ouyang YF, Duan XT, Wang Q, Peng L, Liang JL, Feng ZK, Qin ZH, Liu X, He ZK, Zhang B, Long GX, Jiang YH, Lei F, Huang PY, Hua YJ, Chen MY. You R, et al. Among authors: liu zg. BMJ. 2026 Feb 10;392:e085863. doi: 10.1136/bmj-2025-085863. BMJ. 2026. PMID: 41667193 Free PMC article. Clinical Trial.
354 results